About half of patients had sustained reduction in depression and anxiety up to two years after psilocybin and psychotherapy<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, June 16, 2025 (HealthDay News) — For cancer patients with a major depressive disorder, a single dose of psilocybin combined with psychological support can provide sustained relief for depression and anxiety, according to a study published online June 16 in Cancer<\/em>.<\/p>\n Manish Agrawal, M.D., from Sunstone Therapies in Rockville, Maryland, and colleagues examined efficacy outcomes at two years for patients enrolled in a phase 2 trial that demonstrated safety, feasibility, and efficacy of a single dose of psilocybin combined with psychological support in a community cancer setting involving 30 patients with cancer and a major depressive disorder.<\/p>\n The researchers found that 15 of 28 patients (53.6 percent) had a significant reduction in depression as measured by the Montgomery Asberg Depression Rating Scale (average, \u221215.0 points from baseline) and 14 (50 percent) had a sustained reduction in depression. Overall, 13 patients (46.4 percent) experienced a significant reduction in anxiety as measured by the Hamilton Anxiety Rating Scale (average, \u221213.9 points from baseline), and 12 (42.9 percent) experienced a sustained reduction in anxiety.<\/p>\n “One dose of psilocybin with psychological support to treat depression has a long-term positive impact on relieving depression for as much as two years for a substantial portion of patients with cancer, and we’re exploring whether repeating the treatment resolves depression for more than half of the patients,” Agrawal said in a statement.<\/p>\n Several authors disclosed ties to industry, including Sunstone Therapies.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n